Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1.

Posted on by

“Delta(9)-Tetrahydrocannabinol, the active agent of Cannabis sativa, exhibits well-documented antitumor properties, but little is known about the possible effects mediated by endogenous cannabinoids on human tumors. In the present study, we analyzed the effect of arachidonyl ethanolamide (AEA) on cervical carcinoma (CxCa) cell lines.

The major finding was that AEA induced apoptosis of CxCa cell lines via aberrantly expressed vanilloid receptor-1, whereas AEA binding to the classical CB1 and CB2 cannabinoid receptors mediated a protective effect…

Overall, these data suggest that the specific targeting of VR1 by endogenous cannabinoids or synthetic molecules offers attractive opportunities for the development of novel potent anticancer drugs.”

http://www.ncbi.nlm.nih.gov/pubmed/15047233

http://www.thctotalhealthcare.com/category/cervical-cancer/

Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.

Posted on by

“Drugs that facilitate dopaminergic neurotransmission such as amphetamine induce PPI disruption in human and rodents.

Clinical and neurobiological findings suggest that the endocannabinoid system and cannabinoids may be implicated in the pathophysiology and treatment of schizophrenia.

Cannabidiol (CBD), a non-psychotomimetic constituent of the Cannabis sativa plant, has also been reported to have potential as an antipsychotic.

Our aim was to investigate if CBD pretreatment was able to prevent PPI disruption induced by amphetamine…

Pretreatment with CBD attenuated the amphetamine-disruptive effects…

These results corroborate findings indicating that CBD induces antipsychotic-like effects.

In addition, they pointed to the nucleus accumbens as a possible site of these effects.”

http://www.ncbi.nlm.nih.gov/pubmed/25943166

http://www.thctotalhealthcare.com/category/schizophrenia/

 

Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.

Posted on by

“There is a great need for safe and effective therapies for treatment of infantile spasms (IS) and Lennox-Gastaut syndrome (LGS). Based on anecdotal reports and limited experience in an open-label trial, cannabidiol (CBD) has received tremendous attention as a potential treatment for pediatric epilepsy, especially Dravet syndrome.

We sought to document the experiences of children with IS and/or LGS who have been treated with CBD-enriched cannabis preparations.

Perceived efficacy and tolerability were similar across etiologic subgroups.

Eighty-five percent of all parents reported a reduction in seizure frequency, and 14% reported complete seizure freedom.

Reported side effects were far less common during CBD exposure, with the exception of increased appetite (30%).

A high proportion of respondents reported improvement in sleep (53%), alertness (71%), and mood (63%) during CBD therapy… this study suggests a potential role for CBD in the treatment of refractory childhood epilepsy including IS and LGS…”

http://www.ncbi.nlm.nih.gov/pubmed/25935511

“Safety and side effects of cannabidiol, a Cannabis sativa constituent.”  http://www.ncbi.nlm.nih.gov/pubmed/22129319

“Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa…” http://www.ncbi.nlm.nih.gov/pubmed/19690824

http://www.thctotalhealthcare.com/category/epilepsy-2/

The type 2 cannabinoid receptor regulates susceptibility to osteoarthritis in mice.

Posted on by

“The aim of this study was to evaluate the role of the type 2 cannabinoid receptor (Cnr2) in regulating susceptibility to osteoarthritis in mice.

These studies demonstrate that the Cnr2 pathway plays a role in the pathophysiology of osteoarthritis in mice and shows that pharmacological activation of CB2 has a protective effect.

Further studies of the role of cannabinoid receptors in the pathogenesis of osteoarthritis in man are warranted.”

http://www.ncbi.nlm.nih.gov/pubmed/25937028

http://www.thctotalhealthcare.com/category/osteoarthritis/

The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe?

Posted on by

“In recent years, the endocannabinoid system has emerged as a new therapeutic target in variety of disorders associated with inflammation and tissue injury, including those of the neuronal, liver, renal and cardiovascular system.

The aim of the present review is to elucidate the effect of endocannabinoid system on ischemia reperfusion injury (IRI) in different organs and systems.

Expert opinion: CB2 receptors may play an important compensatory role in controlling tissue inflammation and injury in cells of the neuronal, cardiovascular, liver and renal systems, as well as in infiltrating monocytes/macrophages and leukocytes during various pathological conditions of the systems (atherosclerosis, restenosis, stroke, myocardial infarction, heart, liver and renal failure).

These receptors limit inflammation and associated tissue injury.

On the basis of preclinical results, pharmacological modulation of CB2 receptors may hold a unique therapeutic potential in stroke, myocardial infarction, atherosclerosis, IRI and liver disease.”

http://www.ncbi.nlm.nih.gov/pubmed/25936364

New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.

Posted on by

“Several recent studies suggest that selective CB2 receptor agonists may represent a valid pharmacological approach in the treatment of various diseases due to the absence of relevant psychoactive side effect…

Two compounds showing the best binding and selectivity profile behaved as a full agonist and a partial agonist at the CB2 receptor and induced a concentration-dependent decrease of cell viability on LNCaP, a prostatic cancer cell line expressing CB2 receptor.

Moreover considering that the CB2 receptor is mainly expressed in cells and organs of the immune system, the same compounds were studied for their potential immune-modulatory and anti-inflammatory effects in activated lymphocytes isolated from healthy controls and multiple sclerosis (MS) patients.”

http://www.ncbi.nlm.nih.gov/pubmed/25935384

Cannabis Enhances Bipolar Patients’ Neurocognitive Performance

Posted on by

Image result for medicalnewstoday

“According to a study published online in the journal Psychiatry Research, individuals with bipolar disorder who used cannabis showed higher neurocognitive performance than patients who did not use cannabis.

Researchers at The Zucker Hillside Hospital in Long Island, NY, in collaboration with a team at the Mount Sinai School of Medicine and the Albert Einstein College of Medicine in New York City, examined the difference in cognitive performance among 50 individuals with bipolar disorder who had a history of cannabis use, with 150 bipolar patients who had no history of cannabis use.

The team discovered that patients who used cannabis showed superior neurocognitive performance than those who did not…

“These data could be interpreted to suggest that cannabis use may have a beneficial effect on cognitive functioning in patients with severe psychiatric disorders…””

http://www.medicalnewstoday.com/articles/249006.php

“Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder”  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408776/

Study: Pot May Improve Cognitive Functioning in Bipolar Disorder

Posted on by

4834872285_7168080651_omain.jpg

“Patients with severe psychiatric disorders actually function better in neurocognitive assessments when they have a history of marijuana use.

Patients with bipolar I disorder performed better in neurocognitive assessments when they had a history of marijuana use.”

http://www.theatlantic.com/health/archive/2012/08/study-pot-may-improve-cognitive-functioning-in-bipolar-disorder/261140/

“Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder”  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408776/

Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder.

Posted on by

Figure 1

“The objective of the present study was to compare clinical and neurocognitive measures in individuals with bipolar disorder with a history of cannabis use disorder (CUD) versus those without a history of CUD…

We compared the groups on clinical and demographic variables, as well as on performance on neurocognitive tests…

CUD+ subjects demonstrated significantly better performance on measures of attention, processing speed, and working memory…

Interestingly, bipolar patients with history of CUD had better neurocognitive performance as compared to patients with no history of CUD.

…these analyses indicate an interesting pattern suggesting superior neurocognitive performance among bipolar patients with comorbid CUD when compared to bipolar patients with no history of cannabis use.”

http://www.ncbi.nlm.nih.gov/pubmed/22818174

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408776/

Long-term disease-modifying effect of the endocannabinoid agonist WIN55,212-2 in a rat model of audiogenic epilepsy.

Posted on by

Modulation of the endocannabinoid (eCB) transmission is a promising approach to treating epilepsy.

Animal models can be used to investigate this approach. Krushinsky-Molodkina (KM) rats have, genetically, audiogenic epilepsy. Moreover, in these animals, repeated induction of audiogenic seizures results in a progressive prolongation of the seizures, known as audiogenic kindling.

Administration of the single dose of WIN55,212-2 one hour before the 4th seizure delayed the kindling process by two weeks, without any acute effect on the audiogenic seizures.

CONCLUSIONS:

This result suggests that short-term potentiation of the eCB system might modify the epileptogenic disease process in patients with a progressive course of epilepsy.”

http://www.ncbi.nlm.nih.gov/pubmed/25933961

http://www.thctotalhealthcare.com/category/epilepsy-2/